Supervised Methadone Consumption: Client Issues and Stigma

Anstice, Susan; Strike, Carol; Brands, Bruna

doi:10.1080/10826080802483936

Cited by 133 publications

(105 citation statements)

References 14 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…Berg et al, 2009;Eversman, 2010;Larance et al, 2011;Lin et al, 2010;Philbin & Zhang, 2010) and patient perspectives (e.g. Anstice et al, 2009;Conner & Rosen, 2008;Harris & McElrath, 2012;Lin et al, 2011;Nyamathi et al, 2007;Treloar et al, 2007).…”

Section: Patient Views Of Opioid Pharmacotherapy Bio-delivery Systemsmentioning

confidence: 99%

Patient views of opioid pharmacotherapy biodelivery systems: Qualitative study to assist treatment decision making.

Neale

Tompkins

Strang

2018

Experimental and Clinical Psychopharmacology

View full text Add to dashboard Cite

The technology for delivering opioid pharmacotherapy (OPT) is expanding. It is important to know what OPT patients think of these developments, and to find ways of enabling patients and clinicians to make informed decisions about which bio-delivery system to choose. We explored the views of current and former OPT patients with a history of heroin use to identify factors influencing their preferences regarding routes of OPT administration. Data were generated via seven focus groups conducted in London, United Kingdom. Participants (n=44) considered standard bio-delivery systems (liquid/linctus, tablet, injectables), emergent systems (implants, depot injections), and a hypothetical system (nasal sprays). Groups were audio-recorded, transcribed verbatim, coded using qualitative software, and analyzed inductively via Iterative Categorization. Participants were cautious of, but willing to consider, new ways of receiving OPT and they welcomed having more choice. Their preferences and decision-making processes were influenced by nine interconnected factors: 1. personal dislike of particular bio-delivery systems; 2. desired feelings following OPT administration; 3.perceived effectiveness of OPT bio-delivery systems; 4. concerns about side effects; 5. ability to control the OPT; 6. impact on daily lives; 7. concerns about OPT-related stigma; 8. need for psychosocial support; and 9. personal treatment goals. This complexity may make it difficult for patients and clinicians to evaluate the pros and cons of the expanding array of OPT bio-delivery systems and to arrive at clear conclusions. We therefore use the findings to Article accepted by Experimental and Clinical Psychopharmacology 3 construct a checklist that may facilitate discussions with patients when decisions about OPT need to be made. KEYWORDS

show abstract

Section: Patient Views Of Opioid Pharmacotherapy Bio-delivery Systemsmentioning

confidence: 99%

Patient views of opioid pharmacotherapy biodelivery systems: Qualitative study to assist treatment decision making.

Neale

Tompkins

Strang

2018

Experimental and Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…20 Opioid substitution therapy is also offered at community pharmacies in many countries in Europe, as well as Canada, China, India, Australia and others. [24][25][26][27][28] Sexual health services, including education on preventing transmission of bloodborne infections, are another important harm reduction strategy offered at community pharmacies. In Scotland, community pharmacists feel confident in their ability to engage IDUs and provide them with information on how to prevent acquiring or transmitting HIV, hepatitis B and hepatitis C from sexual activity.…”

Section: Key Pointsmentioning

confidence: 99%

Pharmacists and Harm Reduction: A Review of Current Practices and Attitudes

Watson

Hughes

2012

Can Pharm J

View full text Add to dashboard Cite

Conclusion:As one of the most accessible health care providers, community pharmacists are in an ideal position to provide meaningful services to injection drug users. However, in order to do so, pharmacists require additional support in the form of better health team and system integration, as well as remuneration models. Can Pharm J 2012;145:124-127.e2. health promotion and traditionally refers to policies or programs that are aimed at decreasing the adverse health, social and economic consequences of high-risk behaviours such as drug and alcohol use. 4 For the purposes of this paper, harm reduction services refer to strategies aimed at minimizing the harmful consequences associated with injection drug use and high-risk sexual activity, which are 2 significant social and health issues. Injection drug use accounts for 17% of new cases of HIV infection and approximately two-thirds of new cases of hepatitis C in Canada. 5,6 While the economic burden related to injection drug use is difficult to determine, the lifetime cost of treating each case of HIV infection is $150,000 and it has been estimated that the cost of treating hepatitis C in injection drug users (IDUs) in Canada between 2006 and 2026 will be $3.96 billion. 7,8 With the sequelae of injection drug use and high-risk sexual activity being so costly and burdensome, the implementation of more effective programs aimed at reducing these problems is a priority.Throughout the literature, community pharmacists are acknowledged as important, underutilized resources in preventing the spread of HIV and other blood-borne infections. Pharmacists are recognized as one of the most accessible health care professionals for the general population and are in an ideal position to reach IDUs, who are often socially marginalized and often wish to maintain anonymity. Potential harm reduction roles for community pharmacists that have been identified include the sale of condoms and other safer-sex products, educating on safe-sex practices, selling clean needles/syringes, providing a site for disposal of used needles and syringes and dispensing oral methadone for the treatment of opiate dependence.The purpose of this paper is to provide an overview of pharmacists' involvement in harm reduction services, with a particular focus on research that has evaluated pharmacists' attitudes and barriers toward provision of these services. A review of the literature from 1995 to 2011 was conducted through MEDLINE, PubMed and Scopus using the search terms pharmacist, harm reduction, disease prevention, health promotion, attitudes, competence and barriers. Relevant references of articles identified by the search were also reviewed by both study investigators. To be included in this review, studies had to focus on harm reduction services involving pharmacies, pharmacists' attitudes and identified barriers toward providing such services or both. Articles were excluded if they were not in English or did not meet the above inclusion criteria. Results Current practices in harm reductionOne of t...

show abstract

“…They offer harm reduction services to injection drug users. In Canada, India, China, Australia, and Europe, community pharmacies are centres of opioid substitution therapy, human immune deficiency virus (HIV) and hepatitis prevention services [58][59][60][61][62][63]. A quasi-experimental study conducted in various jurisdictions in Nigeria including Abuja, Kwara, Abia and Edo states indicated that community pharmacists serve as a bridge between patients and physicians and offer varying levels of maternal and child healthcare services.…”

Section: Resultsmentioning

confidence: 99%

Community Pharmacists and Health Promotion Activities in the 21st Century; Maximizing the Expanded Roles for Universal Health Coverage and Population Health Optimization

Brian¹

2017

MOJPH

View full text Add to dashboard Cite

Background: Pharmacy practice has evolved with ever-increasing roles in patient care and providing medicine use information to the community. Efficient public health care services encourage the rapid attainment of universal health coverage in developing countries.Objective: This study was set to examine the role of health promotion activities in local community pharmacy practice. Methods:A narrative overview of health promotion activities among Nigerian pharmacists was described and qualitative syntheses of the findings were obtained from government documents and published articles. An electronic search of the literature was conducted in Embase, Medline and CINAHL using keywords, truncations terms for adjacency search and a logical combination of these search terms.Result: A survey of pharmacists' participation in health promotion activities within two cities in Nigeria showed a 90% participation among respondents, irrespective of whether financial incentives or remunerations were paid for performing these activities or not. Community pharmacists in Nigeria offered free consultation services at various identified pharmacy outlets, making them readily accessible and well placed for achieving wider coverage among the public. Overall, they respondents showed willingness and a positive attitude in all domains of health promotion activities examined. Conclusion:Community pharmacists now have the expanded and evolving roles of preventive and holistic care. The ease of access pharmacists have to patients, has positioned the profession towards the incorporation of advanced health promotion activities and involvement in various stages of awareness campaigns, especially in testing indicator sensitivity to specific targets set for community health in developing regions. The shortage of health care providers in public health facilities, especially in rural areas, could be leveraged by pharmacists who are adequately trained to educate or train the community towards a particular end or attaining set goals. Health promotion interventions driven by pharmacists, in addition to other health professionals, raise awareness levels about adverse effects of medicines and disease outbreaks. Active participation of community pharmacists in health promotion may serve as a needed link in the sustained global push towards providing increased access to essential medicines in developing communities and improving health coverage.

show abstract

Supervised Methadone Consumption: Client Issues and Stigma

Cited by 133 publications

References 14 publications

Patient views of opioid pharmacotherapy biodelivery systems: Qualitative study to assist treatment decision making.

Patient views of opioid pharmacotherapy biodelivery systems: Qualitative study to assist treatment decision making.

Pharmacists and Harm Reduction: A Review of Current Practices and Attitudes

Community Pharmacists and Health Promotion Activities in the 21st Century; Maximizing the Expanded Roles for Universal Health Coverage and Population Health Optimization

Contact Info

Product

Resources

About